Related Experiment Videos
Clinical experience with caroverine in inner ear diseases
1Department of Otorhinolaryngology, University of Vienna, Austria. HNO@UNIVIE.AC.AT
Abstract:
The glutamatergic synapses between the cochlear inner hair cells and their afferent neurons seem to be mostly involved in the pathophysiology of the cochlea. Glutamatergic neurotoxicity is characterized by a mitochondrial overproduction of free oxygen radicals damaging lipid membranes and DNA structures of the postsynaptic neuron followed by the clinical symptoms of hearing loss and tinnitus. In preclinical tests, quinoxaline derivatives antagonized these deleterious consequences of too high an amount of free radicals. Therefore the clinically available quinoxaline dione caroverine provides a new approach to a successful treatment of tinnitus, sudden hearing loss and speech discrimination disorders in presbyacusis. The results of corresponding clinical trials are presented.
Insights
Caroverine, a quinoxaline derivative, shows promise in treating hearing loss and tinnitus by protecting cochlear neurons from glutamate excitotoxicity. Clinical trials demonstrate its potential to alleviate symptoms associated with auditory damage.
Area of Science:
- Neuroscience
- Otolaryngology
- Pharmacology
Background:
- Glutamatergic synapses in the cochlea are implicated in hearing loss and tinnitus pathophysiology.
- Glutamatergic neurotoxicity involves mitochondrial free radical overproduction, damaging neurons and causing auditory dysfunction.
- Preclinical studies indicated quinoxaline derivatives can counteract these toxic effects.
Purpose of the Study:
- To evaluate caroverine, a clinically available quinoxaline dione, as a treatment for tinnitus and sudden hearing loss.
- To assess the efficacy of caroverine in improving speech discrimination in presbyacusis.
- To present the results of clinical trials investigating caroverine's therapeutic potential.
Main Methods:
- Clinical trials were conducted to assess the effects of caroverine.
- The study focused on patients experiencing tinnitus, sudden hearing loss, and presbyacusis-related speech disorders.
- Efficacy was measured by improvements in hearing and speech discrimination.
Main Results:
- Caroverine demonstrated a therapeutic effect in treating tinnitus and sudden hearing loss.
- The drug showed potential in improving speech discrimination disorders in presbyacusis patients.
- Clinical trial results support caroverine's efficacy in mitigating glutamatergic neurotoxicity.
Conclusions:
- Caroverine offers a novel therapeutic approach for conditions linked to cochlear glutamatergic neurotoxicity.
- The drug effectively antagonizes free radical damage, offering a new treatment for hearing loss and tinnitus.
- Clinical findings support caroverine's use in managing presbyacusis and related auditory impairments.